Safety and Efficacy of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

Trial Profile

Safety and Efficacy of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Oxymetazoline (Primary)
  • Indications Erythema
  • Focus Therapeutic Use
  • Acronyms REVEAL 2
  • Sponsors Allergan
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 May 2017 Results from this and one other study (NCT02131636) assessing the Impact Assessment for Rosacea Facial Redness (IA-RFR) outcome, presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 19 Jan 2017 According to an Allergan media release, based on the data from the study, the U.S. Food and Drug Administration (FDA) has approved RHOFADE cream for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top